See more : Hamborner REIT AG (HABA.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Neurocrine Biosciences, Inc. (NBIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurocrine Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Plover Bay Technologies Limited (1523.HK) Income Statement Analysis – Financial Results
- China Public Procurement Limited (1094.HK) Income Statement Analysis – Financial Results
- Nippon Seiki Co., Ltd. (7287.T) Income Statement Analysis – Financial Results
- Wineco Productions, Inc. (WNCP) Income Statement Analysis – Financial Results
- Embotelladora Andina S.A. (AKO-A) Income Statement Analysis – Financial Results
Neurocrine Biosciences, Inc. (NBIX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neurocrine.com
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.89B | 1.49B | 1.13B | 1.05B | 788.10M | 451.24M | 161.63M | 15.00M | 19.77M | 0.00 | 2.92M | 53.14M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 14.59M | 16.80M | 16.00M | 26.10M | 19.20M |
| Cost of Revenue | 39.70M | 23.20M | 14.30M | 10.10M | 7.40M | 4.89M | 1.25M | 35.90M | 33.80M | 14.40M | 13.80M | 11.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.20M | -2.10M | -1.70M | -1.30M | -1.00M |
| Gross Profit | 1.85B | 1.47B | 1.12B | 1.04B | 780.70M | 446.35M | 160.37M | -20.90M | -14.03M | -14.40M | -10.88M | 41.54M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 16.79M | 18.90M | 17.70M | 27.40M | 20.20M |
| Gross Profit Ratio | 97.90% | 98.44% | 98.74% | 99.03% | 99.06% | 98.92% | 99.22% | -139.33% | -70.97% | 0.00% | -372.76% | 78.17% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.07% | 112.50% | 110.63% | 104.98% | 105.21% |
| Research & Development | 565.00M | 463.80M | 328.10M | 275.00M | 200.00M | 160.52M | 121.83M | 94.29M | 81.49M | 46.43M | 39.25M | 37.16M | 30.95M | 31.15M | 35.81M | 55.29M | 81.99M | 97.68M | 106.63M | 115.07M | 177.27M | 108.94M | 74.27M | 40.23M | 29.20M | 21.80M | 19.90M | 12.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.54M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -82.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 887.60M | 752.70M | 583.30M | 433.30M | 354.10M | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.46M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Other Expenses | 143.90M | 0.00 | 105.30M | 164.50M | 154.27M | 0.00 | -20.00K | 13.00K | 11.00K | 18.00K | 16.00K | 14.00K | 42.23M | 73.29M | 70.99M | 15.74M | 94.00M | 90.96M | 97.44M | 87.91M | 80.57M | 96.58M | 0.00 | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| Operating Expenses | 1.60B | 1.22B | 911.40M | 708.30M | 554.10M | 409.46M | 291.73M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 52.39M | 38.80M | 30.10M | 26.90M | 17.30M |
| Cost & Expenses | 1.64B | 1.24B | 925.70M | 718.40M | 561.50M | 414.35M | 292.99M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 50.19M | 36.70M | 28.40M | 25.60M | 16.30M |
| Interest Income | 0.00 | 11.20M | 3.80M | 12.60M | 19.21M | 0.00 | 0.00 | 2.84M | 1.93M | 629.00K | 400.00K | 489.00K | 435.00K | 397.00K | 691.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.60M | 7.10M | 25.80M | 32.80M | 32.00M | 30.53M | 19.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.30M | 15.60M | 10.90M | 8.60M | 7.45M | 4.02M | 2.40M | 1.50M | 1.01M | 827.00K | 671.00K | 657.00K | 694.00K | 1.44M | 3.18M | 7.61M | 9.40M | 10.57M | 10.09M | 7.08M | 3.69M | 3.10M | 2.65M | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| EBITDA | 358.00M | 264.60M | 218.70M | 336.10M | 226.60M | 56.40M | -120.62M | -139.59M | -87.92M | -63.58M | -49.01M | 2.11M | 34.62M | -13.72M | -47.86M | -73.98M | -193.97M | -102.75M | -14.98M | -45.25M | -55.10M | -100.52M | -41.23M | -33.40M | -17.80M | -10.70M | 1.80M | 3.90M |
| EBITDA Ratio | 18.97% | 16.73% | 18.33% | 31.31% | 28.75% | 8.18% | -81.29% | -1,024.27% | -503.13% | 0.00% | -1,824.25% | -3.98% | 39.32% | -36.67% | -1,501.32% | -1,650.74% | -8,891.99% | -261.89% | -12.09% | -52.97% | -52.62% | -558.23% | -101.02% | -236.15% | -107.14% | -20.63% | -11.88% | 2.60% |
| Operating Income | 250.90M | 249.00M | 196.90M | 318.90M | 219.15M | 36.90M | -131.36M | -147.37M | -94.20M | -64.41M | -49.68M | 1.45M | 33.92M | -13.72M | -53.67M | -87.30M | -212.24M | -113.32M | -25.07M | -52.33M | -58.79M | -103.62M | -43.88M | -35.60M | -19.90M | -12.40M | 500.00K | 2.90M |
| Operating Income Ratio | 13.30% | 16.73% | 17.37% | 30.49% | 27.81% | 8.18% | -81.27% | -982.48% | -476.51% | 0.00% | -1,701.88% | 2.72% | 43.82% | -40.96% | -1,817.47% | -2,196.18% | -17,340.03% | -288.82% | -20.24% | -61.44% | -42.27% | -574.20% | -106.40% | -244.04% | -118.45% | -77.50% | 1.92% | 15.10% |
| Total Other Income/Expenses | 81.20M | -35.10M | -1.10M | -56.30M | -25.80M | -15.05M | -11.18M | 6.28M | 5.27M | 3.87M | 3.59M | 3.58M | 3.65M | 5.75M | 2.63M | -1.32M | 4.94M | 6.11M | 2.88M | 6.64M | 28.69M | 9.08M | 7.09M | 7.10M | 200.00K | -7.40M | 4.80M | 3.20M |
| Income Before Tax | 332.10M | 213.90M | 101.40M | 106.70M | 46.50M | 21.84M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -88.61M | -88.61M | -207.30M | -107.21M | -22.19M | -45.69M | -30.10M | -94.54M | -36.79M | -28.51M | -19.70M | -19.80M | 5.30M | 6.10M |
| Income Before Tax Ratio | 17.60% | 14.37% | 8.95% | 10.20% | 5.90% | 4.84% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -3,000.78% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.65% | -21.64% | -523.89% | -89.21% | -195.41% | -117.26% | -123.75% | 20.31% | 31.77% |
| Income Tax Expense | 82.40M | 59.40M | 11.80M | -300.60M | 9.50M | 730.00K | 17.10M | -7.72M | -6.27M | -4.68M | -4.24M | -4.22M | -4.26M | 0.00 | 173.00K | 1.32M | -4.94M | 0.00 | 0.00 | 79.00K | 158.00K | -9.08M | 120.00K | 302.00K | -3.10M | 7.60M | 200.00K | 200.00K |
| Net Income | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.11M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -51.04M | -88.61M | -207.30M | -107.21M | -22.19M | -45.77M | -30.26M | -94.54M | -36.91M | -28.81M | -16.80M | -20.00M | 5.10M | 5.90M |
| Net Income Ratio | 13.23% | 10.38% | 7.90% | 38.94% | 4.69% | 4.68% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -1,728.34% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.74% | -21.75% | -523.89% | -89.50% | -197.48% | -100.00% | -125.00% | 19.54% | 30.73% |
| EPS | 2.56 | 1.61 | 0.95 | 4.37 | 0.40 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.68 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.60 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.30 | 0.39 |
| EPS Diluted | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.67 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.58 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.28 | 0.36 |
| Weighted Avg Shares Out | 97.70M | 95.80M | 94.60M | 93.10M | 91.63M | 95.40M | 87.99M | 86.56M | 84.50M | 74.58M | 66.80M | 65.62M | 55.18M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 36.76M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 17.00M | 15.13M |
| Weighted Avg Shares Out (Dil) | 101.00M | 98.90M | 97.90M | 97.80M | 95.73M | 95.40M | 88.09M | 86.71M | 84.50M | 74.58M | 66.99M | 66.95M | 56.35M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 37.99M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 18.21M | 16.39M |
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Nvidia Isn't The Only Game In Town. Uber Leads 6 Stocks To Watch.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Three top U.S. biotech stocks to buy in April
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Source: https://incomestatements.info
Category: Stock Reports